These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 739345)

  • 41. Allergy to desferrioxamine.
    Romeo MA; Di Gregorio F; Schiliro G
    J Inherit Metab Dis; 1984; 7(3):121. PubMed ID: 6438394
    [No Abstract]   [Full Text] [Related]  

  • 42. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Editorial: Thalassemia major: a problem of iron overload.
    Stockman JA; Oski FA
    Ann Intern Med; 1974 Aug; 81(2):262-3. PubMed ID: 4846109
    [No Abstract]   [Full Text] [Related]  

  • 44. Mechanism of desferrioxamine-induced iron excretion in thalassaemia.
    Hershko C; Rachmilewitz EA
    Br J Haematol; 1979 May; 42(1):125-32. PubMed ID: 465354
    [No Abstract]   [Full Text] [Related]  

  • 45. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
    Flynn DM; Hoffbrand AV; Politis D
    Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
    [No Abstract]   [Full Text] [Related]  

  • 46. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
    Orton RB; de Veber LL; Sulh HM
    Can J Ophthalmol; 1985 Jun; 20(4):153-6. PubMed ID: 4052864
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Iron chelation therapy with deferoxamine in Cooley anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):643-7. PubMed ID: 633031
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [New therapeutic trends in thalassemia: oral chelating agents].
    Carnelli V; Terzoli S; Fossati G; Careddu G; Perri M; Pedrotti L; Mirra N
    Pediatr Med Chir; 1992; 14(3):273-5. PubMed ID: 1528794
    [TBL] [Abstract][Full Text] [Related]  

  • 49. T2* magnetic resonance and myocardial iron in thalassemia.
    Pennell DJ
    Ann N Y Acad Sci; 2005; 1054():373-8. PubMed ID: 16339685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S; Zarei T; Zahedi Z; Karimi M
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sustained normalization of cardiac function by chelation therapy in thalassaemia major.
    Freeman AP; Giles RW; Berdoukas VA; Talley PA; Murray IP
    Clin Lab Haematol; 1989; 11(4):299-307. PubMed ID: 2605872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study.
    Maurer HS; Lloyd-Still JD; Ingrisano C; Gonzalez-Crussi F; Honig GR
    Am J Dis Child; 1988 Mar; 142(3):287-92. PubMed ID: 3344715
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I; Hatzidimitriou-Papazacharia K; Spiliotopoulou J; Tsagarakis N; Digenopoulou E
    Birth Defects Orig Artic Ser; 1988; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract]   [Full Text] [Related]  

  • 54. Desferrioxamine: its use in iron chelation in thalassemia.
    Sharma BK; Choudhury P; Dubey AP
    Indian Pediatr; 1990 Mar; 27(3):314-9. PubMed ID: 2190932
    [No Abstract]   [Full Text] [Related]  

  • 55. Oral ascorbic acid and iron excretion in thalassemic children treated with desferrioxamine-methansulfonate (Desferal).
    Hathirat P; Isarangkura P; Areekul S; Pleehachinda R; Tuntawiroon M
    Birth Defects Orig Artic Ser; 1988; 23(5B):129-33. PubMed ID: 3390535
    [No Abstract]   [Full Text] [Related]  

  • 56. Yersinia enterocolitis in iron overload.
    Kelly DA; Price E; Jani B; Wright V; Rossiter M; Walker-Smith JA
    J Pediatr Gastroenterol Nutr; 1987; 6(4):643-5. PubMed ID: 3430272
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Evaluation of iron overload in thalassemia].
    Piga A; Davico S; Magliano M; Luzzatto L; Sandri A; Gabutti V
    Pediatr Med Chir; 1986; 8(1):9-13. PubMed ID: 3725619
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy.
    Masera N; Rescaldani C; Azzolini M; Vimercati C; Tavecchia L; Masera G; De Molfetta V; Arpa P
    Haematologica; 2008 Jan; 93(1):e9-10. PubMed ID: 18166775
    [No Abstract]   [Full Text] [Related]  

  • 59. [Yersinia infection and hemoglobin disorder. Apropos of 4 cases].
    Pierron H; Gillet R; Perrimond H; Broudeur JC; Soudry G
    Pediatrie; 1990; 45(6):379-82. PubMed ID: 2170907
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major.
    Bronspiegel-Weintrob N; Olivieri NF; Tyler B; Andrews DF; Freedman MH; Holland FJ
    N Engl J Med; 1990 Sep; 323(11):713-9. PubMed ID: 2388669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.